U.S. Food and Drug Administration (FDA) has granted both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to Prizloncabtagene Autoleucel (Prizlon-cel), also known as A-CAR039, an investigational anti-CD20/CD19 bispecific CAR-T therapy for the treatment of patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL). The post AbelZeta Receives FDA RMAT and Fast Track Designations for Prizlon-cel in Relapsed or Refractory Large B-Cell Lymphoma appeared first on AbelZeta .